| Shmuel Tuvia |
Shmuel Tuvia was the founder of Eloxx Pharmaceuticals Ltd. founded in 2013, where he held the position of Chief Operating Officer & Director from 2013 to 2017. Currently, he is the Chief Scientific Officer at Ayala Pharmaceuticals, Inc. since 2022. Dr. Tuvia's former positions include Chief Development Officer at Ukko Inc. from 2020 to 2022 and Vice President-Preclinical Research at Amryt Pharma Plc from 2009 to 2013. Dr. Tuvia's education includes undergraduate and graduate degrees from Tel-Aviv University and a doctorate from Sackler School of Medicine. |
| Andres A. Gutiérrez |
Andres A. Gutiérrez occupies the position of Chief Medical Officer for Biosight Therapeutics, Inc. and Chief Medical Officer & Executive Vice President at Ayala Pharmaceuticals, Inc., Chief Medical Officer at Old Ayala, Inc. (a subsidiary of Ayala Pharmaceuticals, Inc.).
He previously was Medical Director of BioMarin Pharmaceutical, Inc., Chief Medical Officer of Oncolytics Biotech, Inc., Medical Director for Sonoma Pharmaceuticals, Inc., Medical Director-Early Development Immuno-Oncology at Bristol Myers Squibb Co., Director-Gene & Cell Therapy Unit at Instituto Nacional de Ciencias Medicas y Nutricion, Medical Director for Sunesis Pharmaceuticals, Inc., Chief Medical Officer & Executive Vice President at Advaxis, Inc., Medical Director for Proteolix, Inc., Chief Medical Officer at Sellas Life Sciences Group Ltd. and Director-Gene & Cell Therapy Unit at Instituto Nacional de Salud Pública de México.
Dr. Gutiérrez received a doctorate from Universidad Nacional Autónoma de México. |
| Dana Gelbaum |
Dana Gelbaum is currently the Chief Business Officer & General Manager at Ayala Pharmaceuticals, Inc. She previously worked as the Director-Business Development at Recoly NV, Associate-Corporate Finance at Ernst & Young LLP, and VP-Business Development & Commercial Planning at Chiasma, Inc. She also worked as an Associate at Johnson & Johnson Innovation - JJDC, Inc. from 2003 to 2007. Ms. Gelbaum holds a graduate degree and an MBA from Tel-Aviv University. |
| Roy Golan |
Roy Golan is currently the Chief Financial Officer at Biosight Therapeutics, Inc. and Ayala Pharmaceuticals, Inc. He previously worked as the Controller at On Track Innovations Ltd., Senior Consultant at PricewaterhouseCoopers (Israel), Chief Financial Officer at NeuroDerm Ltd., Vice President-Finance at G.I. View Ltd., President & Chief Financial Officer at Meridian Bioscience Israel Ltd., and Chief Financial Officer at ReWalk Robotics Ltd. He also served as the Chief Financial Officer at KCS Ltd. Mr. Golan holds a graduate degree from Bar-Ilan University and an undergraduate degree from The College of Management Academic Studies. |
| David Sidransky |
David Sidransky is the founder of Champions Oncology, Inc. (founded in 2008) and Israel Biotech Fund (founded in 2014). He is currently the Lead Director at Champions Oncology, Inc. and the General Partner at Israel Biotech Fund. Dr. Sidransky's current jobs include being the Chairman at Old Ayala, Inc. (since 2019), Biosight Therapeutics, Inc. (since 2013), Ayala Pharmaceuticals, Inc. (since 2017), Rosetta Genomics Ltd. (since 2009), Orgenesis, Inc. (since 2013), The Sidney Kimmel Comprehensive Cancer Center (since 1994), Immune Pharmaceuticals, Inc., Galmed Pharmaceuticals Ltd. (since 2014), Ascentage Pharma Group International Co., Ltd. (since 2021), Biond Biologics Ltd., Cactus Acquisition Corp. 1 Ltd., Exoprother Medical, The Johns Hopkins University (since 1998), American Society of Clinical Oncology, Inc., Biomerk, Inc., The Johns Hopkins University School of Medicine (since 1994), and The American Association of Cancer Research. Dr. Sidransky's former jobs include being the Chairman at Tamir Biotechnology, Inc. (2007-2020), Vice Chairman at ImClone LLC (2004-2008), Chairman at Old Ayala, Inc. (2017-2023), Independent Director at AMAG Pharma USA, Inc. (2012-2013), Director at AMAG Pharma USA, Inc. (2010-2012), Director at Zila, Inc. (2006-2007), Board of Director at Celsus Therapeutics Plc (2012-2015), Director at Advaxis, Inc. (2013-2015), Director at American Association for Cancer Research (2005-2008), Director at National Institute of Dental & Craniofacial Research, Director at Efranat Ltd., Director at Akari Therapeutics Plc, Director at Cardiff Oncology, Inc., and Senior Editor at Clinical Cancer Research (2005-2008). Dr. Sidransky's education includes an undergraduate degree from Brandeis University (1981) and a doctorate degree from Baylor College of Medicine. |
| Kenneth A. Berlin |
Kenneth A. Berlin is currently the President, Chief Executive Officer & Director at Old Ayala, Inc., Chief Executive Officer & Director at Biosight Therapeutics, Inc., President, Chief Executive Officer & Director at Ayala Pharmaceuticals, Inc., and President at Rosetta Genomics, Inc. He was previously the President & Chief Executive Officer at Rosetta Genomics Ltd., President, Chief Executive Officer, CFO & Director at Advaxis, Inc., Vice President-Franchise Development at Johnson & Johnson, General Manager-Worldwide at Newell Brands, Inc., General Manager at Veridex LLC, and Vice President-Worldwide Franchise Development at Ortho-Clinical Diagnostics, Inc. He received his undergraduate degree from Princeton University and his graduate degree from UCLA School of Law. |
| Robert Jay Spiegel |
Robert Jay Spiegel is the founder of Spiegel Consultants, LLC, which was founded in 2010. He is currently the Vice Chairman at Cyclacel Pharmaceuticals, Inc., an Independent Director at Geron Corp., Athenex, Inc., RenovoRx, Inc., Sun Pharma Advanced Research Co. Ltd., and Ayala Pharmaceuticals, Inc. He is also an Advisor at Warburg Pincus & Company US LLC, an Associate Professor at Weill Cornell Medical College, and a Venture Advisor at Israel Biotech Fund. Dr. Spiegel has held former positions as Chairman at NexImmune, Inc., Independent Director at Capstone Therapeutics Corp., Director at Avior Computing Corp., Independent Director at Edge Therapeutics, Inc., Director at Talon Therapeutics, Inc., Director at Advaxis, Inc., Independent Director at Sucampo Pharmaceuticals LLC, Director at Weifa ASA, Director at The Cancer Institute of New Jersey, Director at CancerCare of New Jersey, Director at Vidac Pharma Ltd., Director-Developmental Therapeutics at New York University Medical Center, Director at PDS Biotechnology Corp., and Independent Director at Old Ayala, Inc. He was also the Chief Medical Officer & Senior Vice President at Schering-Plough Research Institute and Senior Vice President at Worldwide Clinical Research, Inc. Dr. Spiegel holds a doctorate degree from the University of Pennsylvania and an undergraduate degree from Yale University (conferred in 1971). |
| Murray A. Goldberg |
Murray A. Goldberg is an Independent Director at Ayala Pharmaceuticals, Inc. and a Venture Advisor at Israel Biotech Fund. He was previously an Independent Director at Teva Pharmaceutical Industries Ltd., Aerie Pharmaceuticals, Inc., and Old Ayala, Inc. He also served as a Senior Vice President-Administration at Regeneron Pharmaceuticals, Inc. and as the Managing Director-Structured Finance Group at The Chase Manhattan Bank NA. Additionally, he was the Chief Financial Officer, Treasurer & VP-Finance at PharmaGenics, Inc. Goldberg holds an MBA from The University of Chicago, an undergraduate degree from New York University, and a graduate degree from the London School of Economics & Political Science. |
| Vered Bisker-Leib |
Vered Bisker-Leib is the founder of Imara, Inc. She currently holds multiple positions including CEO, CFO, Chief Financial Officer & Director at Compass Therapeutics, Inc., Independent Director at Ayala Pharmaceuticals, Inc., and Manager at Compass Therapeutics LLC. Previously, she served as a Director at Advaxis, Inc., Independent Director at Old Ayala, Inc., Member-Strategic Transactions Group at Bristol Myers Squibb Co., Chief Business Officer at Cydan II, Inc., and Chief Operating Officer at Olivia Ventures, Inc. Dr. Bisker-Leib obtained an MBA and a doctorate from the University of Massachusetts, and an undergraduate degree from Technion-Israel Institute of Technology. |
| Roni A. Appel |
Roni A. Appel founded Spirify Pharma, Inc., where he worked as President. Mr. Appel also currently works at Ayala Pharmaceuticals, Inc., as Independent Director from 2004. Mr. Appel also formerly worked at Advaxis, Inc., as President, CEO, Secretary & Director in 2006, Anima Cell Metrology, Inc., as Chief Executive Officer from 2008 to 2013, Anima Biotech, Inc., as Chief Executive Officer from 2008 to 2013, LVEP, Inc., as Managing Director & Partner from 1999 to 2014, Americana Financial Services, Inc., as Director-Business Development from 1998 to 1999, and Great Expectations & Associates, Inc., as Chief Financial Officer. Mr. Appel received his Masters Business Admin degree in 1998 from The Trustees of Columbia University in The City of New York and graduate degree in 1994 from the University of Haifa. |
